Can I Take Ashwagandha with AOD-9604?

Why This Combination Gets Asked About

AOD-9604 users tend to stack supplements that support body recomposition. Ashwagandha (Withania somnifera) fits that profile because it lowers cortisol, may raise testosterone modestly, and has adaptogenic effects on stress-driven fat storage. The question is whether these overlapping metabolic effects create a problem or a benefit.

No Published Interaction Data Exists

A PubMed search for "AOD-9604 ashwagandha" or "HGH fragment 176-191 Withania" returns zero results. The Natural Medicines Comprehensive Database does not list an interaction entry for this pair. That absence does not confirm safety; it confirms a data gap. What we can do is evaluate each compound's pharmacology and identify where the mechanisms converge.

The Core Concern Is Pharmacodynamic, Not Pharmacokinetic

AOD-9604 is a 15-amino-acid peptide administered subcutaneously. It does not undergo hepatic CYP450 metabolism. Ashwagandha's withanolides are metabolized primarily through CYP3A4 and CYP2D6 pathways 1. Because AOD-9604 bypasses the liver's cytochrome system entirely, traditional drug-drug interaction modeling does not apply here. The relevant questions are about overlapping downstream effects on the HPA axis, thyroid function, and glucose metabolism.

AOD-9604: What It Does and Does Not Do

AOD-9604 is the C-terminal fragment (amino acids 176 to 191) of human growth hormone, with an added tyrosine residue. It was developed to isolate GH's lipolytic action from its diabetogenic and growth-promoting effects.

Lipolysis Without IGF-1 Elevation

In a 12-week randomized trial (N=300), oral AOD-9604 at 1 mg/day produced statistically significant fat loss compared to placebo without raising IGF-1 or altering glucose homeostasis 2. This is the key pharmacologic distinction from full-length GH: AOD-9604 does not activate the JAK2/STAT5 pathway that drives IGF-1 secretion. Its lipolytic signal runs through beta-3 adrenergic receptor stimulation and upregulation of hormone-sensitive lipase in adipocytes 3.

Regulatory and Quality Context

AOD-9604 is not an FDA-approved finished drug. In the United States, it is available through 503A compounding pharmacies. The FDA's guidance on compounded peptides determines which peptides remain eligible for compounding. Quality varies between compounding sources, and certificate-of-analysis verification matters for any peptide in this category.

Ashwagandha: The Pharmacology That Matters for This Stack

Ashwagandha's bioactive withanolides (primarily withaferin A and withanolide D) produce effects across multiple endocrine axes. Three of those axes are relevant when combining it with AOD-9604.

Cortisol Reduction

A 2012 RCT (N=64) using KSM-66 at 600 mg/day showed a 27.9% reduction in serum cortisol after 60 days compared to placebo 4. A separate systematic review of five RCTs confirmed mean cortisol reductions between 14.5% and 27.9% with root extract standardized to at least 5% withanolides 5. This cortisol-lowering effect is the primary reason people stack ashwagandha with fat-loss peptides: chronic cortisol elevation promotes visceral fat deposition and opposes lipolysis.

Testosterone and Reproductive Hormones

In a 2019 RCT (N=57 men), ashwagandha extract at 600 mg/day increased testosterone by 14.7% versus placebo over 8 weeks 6. The American Urological Association does not include ashwagandha in its clinical guidelines for hypogonadism treatment, and the testosterone increase is modest compared to exogenous therapy. For AOD-9604 users, this effect is generally considered additive to body recomposition goals, not a source of interaction concern.

Thyroid Axis Stimulation

This is the interaction axis that warrants the most attention. A 2018 RCT of subclinical hypothyroid patients (N=50) found that ashwagandha root extract at 600 mg/day significantly increased serum T4 and T3 levels over 8 weeks, with TSH decreasing in response 7. In euthyroid individuals, this thyroid-stimulating property is usually subclinical. But it creates a monitoring requirement when stacking with any compound that could independently affect metabolic rate.

Where the Two Compounds Overlap

Three pharmacodynamic domains show potential convergence. None of them represent a contraindication based on current evidence, but each requires awareness.

Domain 1: Cortisol and Lipolysis Cross-Talk

AOD-9604 promotes lipolysis through beta-3 adrenergic signaling. Cortisol opposes lipolysis in visceral adipose tissue through 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity 8. Ashwagandha's cortisol reduction could theoretically amplify AOD-9604's fat-mobilizing effect by removing a counter-regulatory brake. This is a synergistic interaction, not an antagonistic one. The clinical concern would only arise if cortisol dropped below the physiologic floor (morning cortisol <5 µg/dL), which has not been reported in ashwagandha RCTs at standard doses.

Domain 2: Thyroid Function and Metabolic Rate

AOD-9604 has not demonstrated thyroid-stimulating effects in published trials. Ashwagandha has. The overlap risk is one-directional: if ashwagandha pushes thyroid hormones higher in a susceptible individual, the resulting metabolic acceleration could amplify AOD-9604's lipolytic effect beyond what was intended. This is most relevant for people with borderline hyperthyroidism, Graves' disease history, or thyroid nodules. Baseline and 6-week TSH/free T4 monitoring resolves this question for any given patient.

Domain 3: Glucose Metabolism

AOD-9604 was specifically engineered to avoid GH's insulin-antagonist properties, and the Stier et al. Trial confirmed no change in fasting glucose or insulin sensitivity 2. Ashwagandha has shown modest glucose-lowering effects in diabetic populations, with one RCT (N=12) reporting a reduction in fasting blood glucose comparable to oral hypoglycemics over 30 days 9. For most users, this overlap is clinically insignificant. For people on metformin or SGLT2 inhibitors, adding ashwagandha's glucose effect on top of AOD-9604 and an existing diabetic regimen warrants HbA1c monitoring.

Dose Separation and Timing Protocol

No pharmacokinetic interaction necessitates strict separation. The recommendation for a 30 to 60-minute window between subcutaneous AOD-9604 injection and oral ashwagandha is based on general peptide-dosing principles rather than interaction data.

Why Timing Matters for Peptides

Subcutaneous peptides are absorbed through interstitial fluid into capillary and lymphatic circulation. Food and oral supplements in the stomach can trigger insulin release, and insulin may blunt GH-fragment signaling at the adipocyte level. A short separation ensures AOD-9604 reaches peak plasma concentration (typically 15 to 30 minutes post-injection) before ashwagandha's oral absorption begins.

Practical Protocol

• Morning (fasted): AOD-9604 subcutaneous injection
• 30 to 60 minutes later: ashwagandha with breakfast (KSM-66 600 mg or Sensoril 250 mg)
• Alternative split: AOD-9604 in the morning, ashwagandha at bedtime (some users prefer evening dosing for ashwagandha's anxiolytic effects)

The bedtime-split approach eliminates any theoretical insulin-mediated interference entirely.

Monitoring When Using Both

Baseline labs before starting the combination should include TSH, free T4, morning cortisol (drawn before 9 AM), fasting glucose, and a basic metabolic panel.

6 to 8 Week Recheck

After 6 to 8 weeks of concurrent use, repeat TSH, free T4, and morning cortisol. The goal is to confirm that thyroid values remain within reference range and that cortisol has not dropped below 5 µg/dL. If TSH falls below 0.4 mIU/L or free T4 rises above the upper reference limit, ashwagandha should be discontinued and thyroid function reassessed at 4 weeks.

Red Flags That Require Prompt Evaluation

Resting heart rate consistently above 100 bpm, unintentional weight loss exceeding 2 kg per week, tremor, heat intolerance, or insomnia onset after starting the combination could indicate thyroid overstimulation. These symptoms warrant immediate TSH and free T4 testing rather than waiting for a scheduled recheck.

Cortisol Floor Monitoring

If fatigue, orthostatic lightheadedness, or salt cravings develop, check a morning cortisol. Ashwagandha-induced cortisol suppression to the point of adrenal insufficiency symptoms has not been documented in clinical trials, but individual variation exists. A morning cortisol below 5 µg/dL is the threshold for discontinuation and endocrine referral.

Who Should Avoid This Combination

Not everyone is a candidate for co-use.

Autoimmune Thyroid Disease

Ashwagandha's thyroid-stimulating properties make it contraindicated in Graves' disease and potentially problematic in Hashimoto's thyroiditis patients with fluctuating thyroid function. The Endocrine Society's clinical practice guidelines for thyroid disease management recommend against unregulated thyroid-active supplements in autoimmune thyroid patients 10.

Active Cancer Treatment

Ashwagandha has immunomodulatory properties, including increased natural killer cell activity 11. Patients receiving immunotherapy or checkpoint inhibitors should not add immunostimulatory supplements without oncologist clearance.

Pregnancy and Lactation

Ashwagandha is classified as possibly unsafe in pregnancy by the Natural Medicines Comprehensive Database due to abortifacient properties observed in animal studies. AOD-9604 has no human pregnancy safety data. Neither should be used during pregnancy or breastfeeding.

Concurrent High-Dose Thyroid Replacement

Patients on levothyroxine or liothyronine who add ashwagandha may experience thyroid hormone excess. If both ashwagandha and thyroid replacement are desired, thyroid function tests should be repeated 4 to 6 weeks after adding ashwagandha, and levothyroxine dose adjustments may be necessary.

What To Do If You Are Already Taking Both

If you started both compounds without baseline labs, get them now. Order TSH, free T4, morning cortisol, and fasting glucose. If all values fall within reference ranges, the combination can continue with a standard 6 to 8-week monitoring interval. If any value is outside range, work with a clinician to determine whether ashwagandha, AOD-9604, or both need to be paused for retesting.

The most common finding in clinical practice is a mildly suppressed TSH with a normal free T4, which reflects ashwagandha's thyroid stimulation rather than an interaction with AOD-9604. In that scenario, reducing ashwagandha to 300 mg/day or switching to an every-other-day dosing schedule often normalizes TSH within 4 weeks without requiring AOD-9604 discontinuation.

Bottom Line on Safety

The ashwagandha and AOD-9604 combination is not contraindicated by any published evidence. The interaction is pharmacodynamic, not pharmacokinetic, and the overlapping effects on cortisol and metabolic rate are more likely synergistic than harmful in metabolically healthy adults. Standard monitoring (TSH, free T4, morning cortisol at baseline and 6 to 8 weeks) catches the two scenarios that could cause problems: thyroid overstimulation and excessive cortisol suppression. A morning cortisol below 5 µg/dL or a TSH below 0.4 mIU/L is the signal to pause and reassess.